Quan Q

No ORCID on file · 5 papers in corpus · active 2021-2023

Study types

  • article 1
  • other 1

Condition tags

  • endometriosis 2
  • dysmenorrhea 1
other 2023
Endometriosis of the skeletal muscular system (ESMS): a systematic review
BMC women's health ·doi:10.1186/s12905-023-02184-8

BACKGROUND: Extrapelvic endometriosis occurring at skeletal muscle and joint sites is not rare and is prone to delayed diagnosis and inappropriate treatment. Herein, endometriosis of the skeletal muscular system (ESMS) is systematically rev…

2023
The value of serum HE4 and CA125 levels for monitoring the recurrence and risk stratification of endometrial endometrioid carcinoma.
Heliyon ·doi:10.1016/j.heliyon.2023.e18016

To evaluate the role of serum human epididymis secretory protein 4 (HE4) and carbohydrate antigen 125 (CA125) levels for predicting and monitoring the recurrence of endometrial endometrioid carcinoma (EEC) and assessing preoperative risk st…

article 2022
Immune micro-environment and drug analysis of peritoneal endometriosis based on epithelial-mesenchymal transition classification
Frontiers in endocrinology ·doi:10.3389/fendo.2022.1035158

BACKGROUND: Epithelial-mesenchymal transition (EMT) is a complex event that drives polar epithelial cells transform from adherent cells to motile mesenchymal cells, in which are involved immune cells and stroma cells. EMT plays crucial role…

2021
Diagnostic Value of Preoperative CA125, LDH and HE4 for Leiomyosarcoma of the Female Reproductive System.
Cancer management and research ·doi:10.2147/cmar.s302223

PurposeLeiomyosarcoma (LMS) is a rare and extremely aggressive malignancy that is derived from or shows evidence of differentiation toward smooth muscle. If LMS occurs in the female reproductive system, preoperative diagnosis can be difficu…

2021
Serum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma.
Scientific reports ·doi:10.1038/s41598-021-01263-w

There is no recognized serum biomarker to predict the recurrence of endometrial carcinoma (EC). We aimed to explore serum human epididymis protein 4 (HE4) and cancer antigen 125 (CA125) as the biomarkers to predict and monitor recurrence of…